Choose your location to get a site experience tailored for you.

Remember my region and language settings

Our Latest Thinking on Biopharmaceuticals

The biotech and pharma industries continue their fast-paced digital evolution, while geopolitical and economic forces present hurdles that require a fine-tuned strategy throughout the supply chain. Explore BCG’s latest thought leadership on biopharmaceuticals for key insights into the future of the life sciences industry.


Featured Insights

Chasing Value as AI Transforms Health Care

Chasing Value as AI Transforms Health Care

The revolution has come to health care. Artificial intelligence has major repercussions for players across the industry—as well as for new-technology entrants and consumers.

How US Tax Reform Will Affect Biopharma Supply Chains

How US Tax Reform Will Affect Biopharma Supply Chains

Supply chain managers need to ask certain key questions about how the new law will affect their companies’ global networks, investments, and M&A strategies—giving them a better understanding of how to make winning moves.

Biopharmaceuticals in China

China’s Digital Health-Care Revolution

Digital technology is transforming health care in China, and players including pharmaceutical and medtech companies, distributors and retailers, and payers will need to adapt.

Placing Your CAR-T Bets

Placing Your CAR-T Bets

These new therapies are poised to revolutionize oncology. It all depends on reaching a larger patient base and simplifying manufacturing and the supply chain.

What is the Right Amount to Spend on Biopharma R&D?

What Is the Right Amount to Spend on Biopharma R&D?

The most successful companies are those with flexible R&D allocation, according to BCG’s Michael Ringel in an article published in Nature Reviews Drug Discovery. These companies actively pursue and invest in the right new scientific opportunities, balance quantitative and qualitative information on scientific feasibility and market need, employ incentives that drive “truth seeking,” and introduce variability into the cost base to enable flexibility in year-to-year investment levels.

Using Big Data to Help Fight Cancer

Using Big Data to Help Fight Cancer

Innovation in Biopharma R&D

External Innovation Basics from an R&D Expert

Karalee Close on The Digital Opportunity in Healthcare

Frank Cordes on The Pharma Factory of the Future

Mark Lubkeman on A Return to Growth

protected by reCaptcha

Subscribe to our Biopharma eAlert.

Biopharmaceuticals

SUBSCRIBE

EN